Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP

Daiji Nagayama1, 2, Atsuhiato Saiki2, Yasuhiro Watanabe2, Takashi Yamaguchi2, Masahiro Ohira2, Naoko Sato3, Mizuho Kanayama3, Masao Moroi4, Yoh Miyashita5, Kohji Shirai6 and Ichiro Tatsuno2

1 Nagayama Clinic, Tochigi, Japan
2 Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center, Chiba, Japan
3 Pharmaceutical Unit, Toho University Sakura Medical Center, Chiba, Japan
4 Division of Cardiovascular Medicine (Ohashi), Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
5 Medical Correction Center in East Japan, Tokyo, Japan
6 Department of Internal Medicine, Mihama Hospital, Chiba, Japan

Aim: To clarify the mechanism by which pitavastatin reduced cardiovascular (CV) events more effectively than atorvastatin in the TOHO Lipid Intervention Trial Using Pitavastatin (TOHO-LIP), the changes in (Δ) non-heparinized serum level of lipoprotein lipase mass (LPL mass) during administration of the respective statins were investigated.

Methods: From TOHO-LIP data, 223 hypercholesterolemic patients with any CV risks followed at Toho University Sakura Medical Center were analyzed. The patients were randomized to pitavastatin (2 mg/day) group (n=107) or atorvastatin (10 mg/day) group (n=116), and followed for 240 weeks. In this subgroup study, the primary and secondary end points were the same as those in TOHO-LIP, and 3-point major adverse cardiovascular events (3P-MACE) was added. The relationship between ΔLPL mass during the first year and the incidences of each end point was analyzed.

Results: The lipid-lowering effect was not different between the two statins. Cumulative 240-week incidence of each end point was significantly lower in pitavastatin group (primary: 1.9% vs. 10.3%, secondary: 4.7% vs. 18.1%, 3P-MACE: 0.9% vs. 6.9%). Mean LPL mass (64.9 to 69.0 ng/mL) and eGFR (70.1 to 73.6 ml/min/1.73m²) increased in pitavastatin group, but not in atorvastatin group during the first year. Cox proportional-hazards model revealed that ΔLPL mass (1 ng/mL or 1SD) contributed to almost all end points.

Conclusions: Pitavastatin administration reduced CV events more efficaciously than atorvastatin despite similar LDL cholesterol-lowering effect of the two statins. Increased LPL mass during the first year by pitavastatin treatment may be associated with this efficacy.

Key words: Pitavastatin, Atorvastatin, Low-density lipoprotein cholesterol, Lipoprotein lipase, Cardiovascular disease

Introduction

The significance of lowering low-density lipoprotein cholesterol (LDL-C) level in the reduction of cardiovascular (CV) disease in both primary and secondary prevention has been reported1, 2). Hydroxymethylglutaryl (HMG)-CoA reductase inhibitors, also known as statins, inhibit the
production of mevalonic acid from HMG-CoA, leading to upregulation of hepatic LDL receptor and resulting in potent LDL-C-lowering effect\(^3\). Atorvastatin, one of the most used statins all over the world, was established to be efficacious in primary and secondary prevention of CV events in hypercholesterolemic patients\(^4, 9\).

Pitavastatin is a statin with a chemical structure and pharmacokinetic profile different from those of atorvastatin, and has been clinically available in Japan since 2003 for the treatment of primary hyperlipidemia or mixed dyslipidemia\(^6\). Study showed greater increases in high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-1 levels in hypercholesterolemic patients treated with pitavastatin than with atorvastatin\(^7\). Several pleiotropic effects of pitavastatin may lead to the reduction of CV risk. For example, pitavastatin treatment was shown to improve endothelial function\(^8\), anti-oxidative and anti-inflammatory condition\(^9\) and coronary plaque stabilization\(^10\). Besides, compared with atorvastatin, favorable effects of pitavastatin on glucose metabolism\(^11-13\) and lipid metabolism irrespective of obesity-related parameters\(^7, 14\) were observed. However, it remained unclear whether pitavastatin was as effective as atorvastatin in preventing CV events.

We therefore conducted a multicenter, open-label, randomized controlled trial of head-to-head comparison between pitavastatin and atorvastatin, named the TOHO Lipid Intervention Trial Using Pitavastatin (TOHO-LIP)\(^15\). This trial, which enrolled 664 hypercholesterolemic patients with one or more CV risks, revealed that pitavastatin (2 mg/day) therapy was superior to atorvastatin (10 mg/day) therapy in the prevention of primary end point which was a composite of CV death, sudden death of unknown origin, nonfatal myocardial infarction (MI), nonfatal stroke, transient ischemic attack and heart failure requiring hospitalization [pitavastatin: 2.9%, atorvastatin: 8.1%, hazard ratio (HR): 0.366], despite similar LDL-C-lowering effect. In this trial, C-reactive protein (CRP) level only in the limited population of pitavastatin group was reduced during the first year. Additionally, in a subgroup analysis of TOHO-LIP, Saiki et al.\(^16\) reported that the reduction in CV events by pitavastatin treatment tended to be associated with decreased arterial stiffness. However, the mechanism by which pitavastatin preferentially prevents CV events is not fully elucidated.

Lipoprotein lipase (LPL), which is thought to be anchored on the surface of endothelial cells and hydrolyzes triglyceride (TG) in the blood, is mainly produced in adipocytes and skeletal muscle cells\(^17\). Generally, the measurement of LPL activity and LPL mass are conducted using plasma after a heparin injection, which releases LPL from the surface of endothelial cells into blood\(^18\). On the other hand, a sensitive immunoassay system using a specific monoclonal antibody against LPL can detect LPL mass in serum without heparin injection, although the LPL mass in heparin serum has no activity\(^19, 20\). The preheparin serum level of LPL mass (abbreviated as LPL mass hereinafter) correlates negatively with BMI and intra-abdominal visceral fat area evaluated by computed tomography\(^21\). Additionally, LPL mass also correlated negatively with the severity of metabolic syndrome, type 2 diabetes\(^22-25\) and coronary atherosclerosis\(^26, 27\). These findings indicate that low LPL mass reflects insulin resistance and risk of coronary artery disease. Furthermore, insulin-sensitizing therapies including body weight reduction\(^28\), insulin therapy\(^29\) and administration of troglitazone, a PPAR\(\gamma\) enhancer\(^30\), also increased LPL mass in patients with metabolic syndrome. Especially, pitavastatin is known to enhance LPL expression in both 3T3L1 preadipocyte\(^31\) and L6 skeletal muscle cells\(^32\). Moreover, it has been reported that pitavastatin was more effective than atorvastatin in increasing LPL mass in Japanese patients\(^33\). With these backgrounds, we posed the research questions of whether pitavastatin increases LPL mass, and whether the change in (Δ) LPL mass is associated with the incidence of CV event in hypercholesterolemic patients.

Therefore, we investigated the relationship between the incidences of CV events and annual Δ LPL mass during the first year in a subgroup of subjects in TOHO-LIP, who were followed at the Toho University Sakura Medical Center.

**Subjects and Methods**

The rationale, study design, inclusion criteria, and other details of the TOHO-LIP are described elsewhere\(^15\). This multicenter randomizes open-label trial compared head-to-head two lipid-lowering drugs; pitavastatin and atorvastatin, regarding the prevention of CV events in middle-aged or older patients with hypercholesterolemia at high risk of atherosclerotic CV disease.

From April 1, 2006 to May 31, 2011, a total of 664 patients were enrolled from 3 medical centers of Toho University (Japan) and randomized to receive either pitavastatin or atorvastatin. The dose of pitavastatin used was 2 mg/day, which is known to exert LDL-C-lowering effect comparable to that of atorvastatin 10 mg/day\(^10\). The optimal treatment target was set at LDL-C<100 mg/dL. The duration of treatment with the statins was 240 weeks. The
estimated glomerular filtration rate (eGFR) was calculated by the following equation:
\[ \text{eGFR (mL/min/1.73m²)} = 194 \times \text{Creatinine}^{-1.094} \times \text{age} - 0.287 \times (0.739 \text{ if female}). \]

In the present subgroup analysis, we studied the subjects in TOHO-LIP recruited from a single center. From the database of TOHO-LIP, 390 outpatients who attended the Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center (Chiba, Japan) were included. All participants in this study were outpatients, and blood samplings were taken sitting in a chair. Among them, patients with LPL mass data obtained both at baseline and one year later were enrolled. Eventually, 223 patients were analyzed (pitavastatin group: 107 patients, atorvastatin group: 116 patients).

LDL-C was calculated using Friedewald formula: LDL-C = total cholesterol (TC) – (HDL-C) – (TG/5).

Since this formula is not valid for patients with TG ≥ 400 mg/dL, subjects with TG ≥ 400 mg/dL (3.1% of all participants) were excluded from the analysis of LDL-C. The LPL mass in serum was measured by a specific monoclonal antibody against LPL (Sekisui sandhi) by sandwich enzyme-linked immunosorbent assay using a standard enzyme multi-analyte reagent kit (TOHO-LIP15) were adopted in this subgroup study.

End Points

The primary and secondary end points used in TOHO-LIP were adopted in this subgroup study. The primary end point was a composite of CV death, sudden death of unknown origin, nonfatal acute MI, nonfatal stroke, transient ischemic attack, or heart failure requiring emergency hospitalization. Secondary end point was a composite of the primary end point plus coronary revascularization for stable angina. Additionally, in the present subgroup analysis, 3-point major adverse cardiovascular events (3P-MACE: nonfatal stroke, nonfatal MI, or CV death) was assessed as another composite end point.

Note that LPL mass at one year after randomization were measured in all participants, even if any endpoint occurred during the first year.

Statistical Analysis

The results are expressed as mean ± standard error (SE) only for ΔLPL mass or mean ± standard deviation (SD) for other variables. Wilcoxon signed-rank test was used to compare all parametric data between baseline and after one year of treatment. Mann-Whitney U-test or Fisher's exact test was performed to compare the characteristics between two different groups. Kaplan–Meier survival analysis was employed to estimate the time to end point, and log-rank test was used between two groups. Spearman rank correlation coefficient (Spearman’s ρ) was used to determine the relation between LPL mass and coronary risks. Cox proportional-hazards analysis was performed to examine the contribution of ΔLPL mass to each end point, and the result is expressed as hazard ratio with 95% confidence interval. A two-sided P value of 0.05 was considered statistically significant. Statistical analyses were performed with EZR (Version 1.40, Saitama Medical Center, Jichi Medical University, Saitama, Japan).19

Results

Participants Characteristics at Baseline and after One Year of Treatment in Pitavastatin and Atorvastatin Groups

Participant characteristics of the two statin groups at baseline and after one year are shown in Table 1. No significant differences in all baseline continuous variables were detected between two groups when analyzed by Mann-Whitney U-test. After one year of treatment, TC, TG and LDL-C decreased, and HDL-C increased in both groups. In all participants, mean LDL-C decreased from 161.5 to 99.7 mg/dL, and 59.4% of the participants (pitavastatin: 58.5%, atorvastatin: 61.2%) achieved the target of LDL-C < 100 mg/dL. On the other hand, LPL mass increased significantly from baseline to one year after treatment only in pitavastatin group (pitavastatin: 64.9 to 69.0; atorvastatin: 61.2% to 65.0 ng/mL). Additionally, pitavastatin group also showed significant increase in eGFR (70.1 to 73.6 ml/min/1.73m²).

There were no significant differences in prevalence of macrovascular disease, smoking status, risk factors and medications between two groups when analyzed by Fisher’s exact test. In both groups, over 90% of the participants had diabetes, almost 70% had hypertension, and less than 10% had a history of ischemic heart disease. Additionally, no significant change in the frequency of use of each medication after one year was observed in both groups.

The adverse event rate during the 240-week
In this subgroup analysis of 223 participants, we performed Kaplan-Meier survival analysis to reexamine the difference between two groups as shown in Fig. 1. The cumulative 240-week incidence of each end point was: pitavastatin 1.9% (2/107), atorvastatin 10.3% (12/116) (*P<0.009) for primary end point (Fig. 1a); pitavastatin 4.7% (5/107), atorvastatin 18.1% (21/116) (*P=0.002) for secondary end point (Fig. 1b). Furthermore, the risk of 3P-MACE was also significantly lower in the pitavastatin group (*P=0.009 vs. baseline, Wilcoxon signed-rank test).

Table 1. Subjects characteristics at baseline and after one year of treatment in pitavastatin and atorvastatin groups

|                          | Pitavastatin (N=107) | Atorvastatin (N=116) |
|--------------------------|-----------------------|-----------------------|
|                          | Baseline              | After one year        | Baseline              | After one year        |
| Male (%)                 | 42.1 - 41.4           | 41.4 -                | 42.4 - 45.7           | 45.7 -                |
| Age (years)              | 63.9 ± 10.6           | 66.0 ± 8.4            | 63.8 ± 8.4            | 76.9 ± 9              |
| Smoking status (%)       |                       |                       |                       |                       |
| Never                    | 72.0 -                | 67.2 -                | 71.4 -                | 73.1 -                |
| Former                   | 21.5 -                | 28.5 -                | 28.7 -                | 27.8 -                |
| Current                  | 6.5 -                 | 4.3 -                 | 6.9 -                 | 5.3 -                 |
| BMI (kg/m²)              | 24.6 ± 4.0            | 24.2 ± 4.0            | 24.5 ± 3.1            | 24.4 ± 3.2            |
| Systolic BP (mmHg)       | 133 ± 16              | 137 ± 17              | 131 ± 15              | 131 ± 15              |
| Diastolic BP (mmHg)      | 77 ± 10               | 79 ± 10               | 76 ± 9                | 76 ± 9                |
| HbA1c (%)                | 7.0 ± 1.1             | 7.1 ± 1.2             | 7.3 ± 1.4             | 7.3 ± 1.4             |
| LPL mass (ng/mL)         | 64.9 ± 23.6           | 69.0 ± 22.3           | 65.9 ± 20.5           | 65.0 ± 21.6           |
| TC (mg/dL)               | 253 ± 39              | 245 ± 39              | 176 ± 30*             | 169 ± 30              |
| TG (mg/dL)               | 157 (111 – 225)       | 115 (84 – 178)*       | 136 (103 – 180)       | 109 (82 – 142)*       |
| HDL-C (mg/dL)            | 54 ± 13               | 57 ± 14*              | 56 ± 13               | 57 ± 14*              |
| LDL-C (mg/dL)            | 164 ± 35              | 103 ± 30*             | 159 ± 34              | 97 ± 27*              |
| Creatinine (mg/dL)       | 0.78 ± 0.26           | 0.75 ± 0.27*          | 0.79 ± 0.21           | 0.79 ± 0.22           |
| eGFR (ml/min/1.73m²)     | 70.1 ± 17.2           | 73.6 ± 18.5           | 67.8 ± 15.3           | 67.9 ± 15.5           |
| Prevalence of diabetes (%)| 92.2 -                | 94.4 -                |                       |                       |
| Prevalence of hypertension (%)| 69.0 -            | 69.2 -                |                       |                       |
| History of ACS and/or coronary revascularization (%)| 7.5 -            | 9.5 -                |                       |                       |
| Stroke (%)               | 5.6 -                 | 6.0 -                 |                       |                       |
| Peripheral artery disease (%)| 1.9 -              | 3.4 -                |                       |                       |
| Medication (%)           |                       |                       |                       |                       |
| Antihypertensive drugs   |                       |                       |                       |                       |
| ACE-I and/or ARB         | 46.7 -                | 48.6 -                | 42.4 - 45.7           |                       |
| Calcium channel blocker  | 43.0 -                | 44.9 -                | 39.7 - 39.7           |                       |
| Diuretics                | 12.1 -                | 16.8 -                | 15.5 - 14.7           |                       |
| Beta-receptor antagonist | 16.8 -                | 17.8 -                | 8.6 - 9.5             |                       |
| Antidiabetes             |                       |                       |                       |                       |
| Insulin                  | 21.5 -                | 24.3 -                | 22.4 - 28.4           |                       |
| Sulfonylurea             | 52.3 -                | 48.6 -                | 50.9 - 52.6           |                       |
| Biguanide                | 30.8 -                | 31.8 -                | 27.6 - 34.5           |                       |
| Thiazolidinedione        | 15.0 -                | 16.8 -                | 14.7 - 12.1           |                       |

Data are presented as mean ± SD or percentage, or median (inter quartile range). *P<0.01 vs. baseline, Wilcoxon signed-rank test.

BMI, body mass index; BP, blood pressure; HbA1c, glycated hemoglobin; LPL, lipoprotein lipase; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ACS, acute coronary syndrome; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SD, standard deviation.

In the TOHO-LIP main study, pitavastatin significantly reduced the risk of the primary and secondary end points compared with atorvastatin. In this subgroup analysis of 223 participants, we performed Kaplan-Meier survival analysis to reexamine the difference between two groups as shown in Fig. 1.

The study period of this subgroup analysis was 1.9% in pitavastatin (1 muscle pain and 1 cholecystitis), and 4.3% in atorvastatin group (4 muscle pain and 1 Alzheimer’s disease). Rhabdomyolysis was not observed in all participants.
reduced in pitavastatin group pitavastatin 0.9% (1/107), atorvastatin 6.9% (8/116), \(P = 0.021\) (Fig. 1c). The results of primary and secondary end points were almost equal to those in the main TOHO-LIP study.

In this subgroup analysis, the incidence of heart failure requiring hospitalization was pitavastatin 1.9% (2/107) and atorvastatin 2.6% (3/116). Of the two patients in the pitavastatin group, only one was initially receiving a beta-receptor antagonist, and none was receiving a diuretic. Also, of the three patients in the atorvastatin group, none were initially receiving a beta-receptor antagonist and only two were receiving a diuretic. These results therefore suggest that the frequency of diuretics/beta-receptor antagonist administration had little effect on the difference in end points between the two groups in this study.

**Fig. 1.** Kaplan-Meier curves for the primary end point (a), secondary end point (b) and 3P-MACE (c) for pitavastatin and atorvastatin group

Primary end point was a composite of cardiovascular death, sudden death of unknown origin, nonfatal acute myocardial infarction, nonfatal stroke, transient ischemic attack, and heart failure requiring hospitalization. Secondary end point was a composite of the primary end point plus coronary revascularization. 3P-MACE was a composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death. 3P-MACE, 3-point major adverse cardiac event.

**Fig. 2.** Comparison of change in LPL mass during the first year between pitavastatin and atorvastatin group

Data are expressed as mean ± standard error. \( *P < 0.05\) using Mann-Whitney’s \( U \) test. LPL, lipoprotein lipase.

**Comparison of Characteristics at Baseline and Changes during the First Year in Subjects with or without Secondary End Point**

Next, we investigated the characteristics of
subjects who had vascular events during the 240-week study period. We examined the secondary end point because the number of cases was the largest among the three end points. All subjects were divided into two groups based on the presence or absence of the secondary end point. In addition, each group was divided into pitavastatin and atorvastatin groups. The differences in baseline characteristics and their changes during the first year between are compared in Table 2.

Subjects without secondary end point had lower prevalences of hypertension, male ratio and history of ACS and/or coronary revascularization, and higher prevalence of diabetes. These confounders required adjustment when the association of ΔLPL mass with each end point was analyzed by Cox proportional-hazards model (to be shown below).

Subjects with secondary end points showed higher frequency of diuretics (P=0.064) and biguanide (P=0.020). These medications were not recruited as the adjusting factor for ΔLPL in Table 4 because of their intraclass correlations to history of ACS and/or coronary revascularization. Note that the mean ΔLPL mass during the first year in subjects without secondary end point tended to be higher than that in subjects with secondary end points (2.2 vs. -5.7, P=0.065), even though their mean baseline LPL mass were equal.

There was no difference in change in BP between pitavastatin and atorvastatin groups as shown in Table 1. However, in subjects without secondary end point, atorvastatin group showed greater decrease in BP. Besides, the greater increase in eGFR was observed also in pitavastatin group without secondary end point.

**Association of Baseline and Annual Change in LPL Mass with Risk Factors**

The association of LPL mass with clinical characteristics are shown in Table 3.

Baseline LPL mass correlated positively with age (ρ=0.172) and HDL-C (ρ=0.393), and negatively with BMI (ρ=-0.246) and TG (ρ=-0.356) at baseline. Significantly lower LPL mass was observed in subjects with TG ≥ 150 mg/dL (mean value, yes vs. no: 60.0 vs. 70.2 ng/mL), BMI ≥ 25 kg/m² (59.5 vs. 68.2 ng/mL), history of ACS and/or coronary revascularization (54.8 vs. 66.1 ng/mL), and in men (56.5 vs. 71.6 ng/mL).

Next, in each statin group, we compared the annual change in LPL mass between various two categorical groups. Resultantly, higher increase in annual change in LPL mass was observed in hypertensive subjects (6.5 vs. 5.7) or subjects with TG ≥ 150 mg/dL (6.6 vs. 3.8 ng/mL) in pitavastatin group. Additionally, annual ΔLPL mass during the first year did not correlate with changes in any metabolic parameters in both groups.

Saiki et al. reported in another subgroup analysis of TOHO-LIP that systemic arterial stiffness assessed by cardio-ankle vascular index (CAVI) decreased only in pitavastatin group. On the other hand, in the present study, CAVI did not significantly decrease in pitavastatin group (9.34 to 9.30, P=0.176). However, ΔLPL was significantly correlated with ΔCAVI in all participants (Spearman’s ρ=-0.352, P<0.001) (data not shown).

**Comparison of Changes in LPL Mass during the First Year between Pitavastatin and Atorvastatin Group**

Furthermore, we compared ΔLPL mass between pitavastatin and atorvastatin groups. As shown in Table 1, LPL mass increased during the first year only in pitavastatin group. Besides, mean ΔLPL mass in pitavastatin group was significantly higher compared with that in atorvastatin group (4.03 vs. -0.87 ng/mL, P=0.023) (Fig. 2).

**Association of Change in LPL Mass during the First Year with Each End Point**

Next, the contribution of ΔLPL mass to each end point was examined using Cox proportional-hazards model (Table 4). After adjusting for confounders of gender, diabetes, hypertension and history of ACS and/or coronary revascularization (Table 2) in Model 1, ΔLPL mass (1 ng/mL or 1 SD increase) contributed roughly to the primary, secondary, and 3P-MACE end points. However, only the contribution of ΔLPL mass (1SD increase) to the primary end point was not significant (P=0.082).

In Model 2, we added pitavastatin administration as a confounder. Resultantly, the significant contributions of ΔLPL for primary end point (1 ng/mL and 1 SD increase) and for 3P-MACE (1 SD increase) partially disappeared, indicating the intraclass correlation between pitavastatin administration and ΔLPL.

**Discussion**

In this subgroup analysis of TOHO-LIP, we reconfirmed that pitavastatin therapy was superior to atorvastatin therapy in the prevention of CV events, and compared ΔLPL mass during the first year between the two statin groups. LPL mass and eGFR increased only in pitavastatin group, and the annual increase in LPL mass during the first year contributed to the reduction of cumulative 240-week incidence of
Table 2. Comparison of characteristics at baseline and changes during the first year in subjects with or without secondary end points

|                                | Subjects without secondary end point | Subjects with secondary end point |
|--------------------------------|--------------------------------------|----------------------------------|
|                                | Total (N=197)                        | Pitavastatin (N=102)            |
| Male (%)                       | 39.6                                 | 40.2                             |
| Age (years)                    | 64.8 ± 9.8                           | 63.7 ± 10.9                      |
| BMI ≥ 25 kg/m² (%)             | 24.7 ± 3.5                           | 24.7 ± 3.9                       |
| ΔBMI (kg/m²)                   | -0.23 ± 0.9                          | -0.4 ± 1.3                       |
| Baseline systolic BP (mmHg)    | 135 ± 16                             | 134 ± 16                         |
| ΔSystolic BP (mmHg)            | -4 ± 17                              | -1 ± 16                           |
| Baseline diastolic BP (mmHg)   | 78 ± 11                              | 78 ± 11                           |
| ΔDiastolic BP (mmHg)           | -2 ± 9                               | 0 ± 9    ± 8                      |
| Hypertension (%)               | 66.0                                 | 67.6                              |
| Diabetes (%)                   | 0.1 ± 0.9                            | 0.1 ± 1.0                         |
| Baseline LPL mass (ng/mL)      | 65.7 ± 22.4                          | 65.5 ± 23.9                      |
| ΔLPL mass (ng/mL)              | 2.2 ± 15.6                           | 3.7 ± 15.5                       |
| Baseline TC (mg/dL)            | 250 ± 37                             | 254 ± 38                         |
| ΔTC (mg/dL)                    | -66 ± 38                             | -64 ± 36                         |
| Baseline TG (mg/dL)            | 148 (105–203)                        | 158 (109–225)                    |
| ΔTG (mg/dL)                    | -27 (-63–5)                          | -69 (-560–203)                   |
| Baseline HDL-C (mg/dL)         | 55 ± 13                              | 54 ± 13                           |
| ΔHDL-C (mg/dL)                 | 8.1                                 | 12.7                              |
| Baseline LDL-C (mg/dL)         | 162 ± 34                             | 165 ± 35                         |
| ΔLDL-C (mg/dL)                 | -62 ± 33                             | -63 ± 31                         |
| eGFR (ml/min/1.73m²)           | 69.5 ± 16.4                          | 70.7 ± 17.3                      |
| eGFR (ml/min/1.73m²)           | 1.7 ± 9.3                            | 3.4 ± 10.3                       |
| History of ACS and/or coronary revascularization (%) | 5.1 | 4.9 | 5.3 | 34.6** | 60.0 | 28.6 |

Data are presented as mean ± SD, or median (inter quartile range). *P<0.10 and **P<0.05, comparison between total subjects with and without secondary end point groups. P<0.05, comparison between pitavastatin and atorvastatin groups. Mann-Whitney’s U test or Fisher’s exact test.

BMI, body mass index; BP, blood pressure; HbA1c, glycated hemoglobin; LPL, lipoprotein lipase; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SD, standard deviation.
gender, obesity and coronary artery disease. These findings of LPL mass are consistent with previous reports (22-25), reconfirming low LPL mass as a CV risk. Additionally, the contribution of increased LPL mass to primary, secondary end points and 3P-MACE. Furthermore, baseline LPL mass correlated positively with age and HDL-C, and negatively with BMI and TG. Relatively low LPL mass was associated with male

**Table 3.** Association between baseline / annual change in LPL mass and risk factors

| Categorical variable | Comparison of baseline LPL mass (ng/mL) | Coefficient of correlation with annual change in LPL mass |
|---------------------|-----------------------------------------|--------------------------------------------------------|
| Pitavastatin / Atorvastatin | 64.9 ± 23.6 / 65.9 ± 20.5 | vs. Pitavastatin / Atorvastatin |
| Sex, males/females | 56.5 ± 20.1 / 71.6 ± 21.3 | -0.246* |
| Hypertension, Yes/No | 64.2 ± 22.9 / 67.9 ± 19.9 | -0.082 |
| TG > 150 mg/dL, Yes/No | 60.0 ± 23.8 / 70.2 ± 19.2 | -0.356* |
| Diabetes, Yes/No | 65.3 ± 22.1 / 67.3 ± 21.2 | -0.007 |
| eGFR < 60 ml/min/1.73m², Yes/No | 65.3 ± 22.2 / 65.4 ± 22.0 | 0.015 |
| BMI ≥ 25kg/m², Yes/No | 59.5 ± 23.7 / 68.2 ± 20.7* | -0.062 |
| History of ACS and/or Coronary revascularization, Yes/No | 54.8 ± 16.7 / 66.1 ± 22.2* | 0.172* |

| vs. | Coefficient of correlation with baseline LPL mass |
|-----|--------------------------------------------------------|
| Age (years) | 0.172* |
| BMI (kg/m²) | -0.246* |
| Systolic BP (mmHg) | -0.082 |
| HbA1c (mg/dL) | -0.007 |
| TC (mg/dL) | 0.008 |
| TG (mg/dL) | -0.356* |
| HDL-C (mg/dL) | 0.393* |
| LDL-C (mg/dL) | 0.015 |
| eGFR (ml/min/1.73m²) | -0.062 |

| Categorical variable | Annual change in LPL mass (ng/mL) |
|---------------------|-----------------------------------|
| Sex, males/females | 5.9 (-1.3 – 14.0) / 5.6 (-8.3 – 14.3) | -0.007 |
| Hypertension, Yes/No | 6.5 (-1.4 – 15.7) / 5.7 (-12.7 – 11.0) | -0.073 |
| TG > 150 mg/dL, Yes/No | 6.6 (-3.7 – 14.6) / 3.8 (-2.8 – 11.0) | -0.010 |
| Diabetes, Yes/No | 5.9 (-3.7 – 14.4) / 4.9 (-2.0 – 10.4) | 0.013 |
| eGFR < 60 ml/min/1.73m², Yes/No | 4.9 (-5.9 – 12.1) / 6.6 (-2.4 – 14.4) | -0.147 |
| BMI ≥ 25kg/m², Yes/No | 7.1 (-0.4 – 13.2) / 5.7 (-3.9 – 14.2) | 0.036 |
| History of ACS and/or Coronary revascularization, Yes/No | 10.4 (0.8 – 17.6) / 5.8 (-5.1 – 14.2) | 0.068 |

| vs. | Coefficient of correlation with annual change in LPL mass |
|-----|--------------------------------------------------------|
| ΔBMI (kg/m²) | -0.007 |
| ΔSystolic BP (mmHg) | -0.073 |
| ΔHbA1c (mg/dL) | -0.010 |
| ΔTC (mg/dL) | 0.013 |
| ΔTG (mg/dL) | -0.147 |
| ΔHDL-C (mg/dL) | 0.036 |
| ΔLDL-C (mg/dL) | 0.068 |
| ΔeGFR (ml/min/1.73m²) | -0.174 |

*P < 0.05, Spearman’s coefficient of correlation (ρ). †P < 0.05, Mann-Whitney’s U test to compare two categorical groups. Data of baseline or annual change in LPL mass are presented as mean ± SD or median (inter quartile range).

LPL, lipoprotein lipase; eGFR, estimated glomerular filtration rate; BMI, body mass index; BP, blood pressure; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ACS, acute coronary syndrome.
enhancing nitric oxide production\textsuperscript{9, 36}). Besides, Hitsumoto \textit{et al.}\textsuperscript{26} reported the implication of low LPL mass as a marker of coronary vasospasm in early stage atherosclerosis, which is characterized by endothelial dysfunction. Additionally, we previously found the association of CAVI with endothelial function assessed by flow-mediated dilation\textsuperscript{37}), and the fact that appropriate therapeutic approaches in diabetic patients simultaneous improved CAVI and LPL mass\textsuperscript{25, 38}). We therefore speculate that, in TOHO-LIP, pitavastatin-induced improvement of endothelial function was expressed as decreased CAVI and increased LPL mass. Kobayashi \textit{et al.}\textsuperscript{ also reported that atorvastatin administration did not change LPL mass in Japanese hyperlipidemic subjects\textsuperscript{39}). In contrast, in subjects with low LPL mass (less than 50 ng/mL), atorvastatin has been reported to increase LPL mass\textsuperscript{40}). There were few patients with low LPL mass in the present study, which may have led to the different result. Furthermore, our previous \textit{in vitro} study revealed that atorvastatin enhanced LPL expression in skeletal muscle, but not in adipose tissue. On the contrary, pitavastatin enhances LPL expression also in adipose tissue, resulting in stronger increase in LPL mass in whole body than atorvastatin\textsuperscript{31, 32}).

Second, elimination of insulin resistance by pitavastatin may exert a direct or indirect anti-arteriosclerotic effect. LPL, which degrades circulating to the reduction of each end point was independent of gender, diabetes, hypertension and coronary artery disease. These findings about LPL mass may partially explain the mechanism by which pitavastatin reduces CV events.

In the main TOHO-LIP study, CRP level decreased during the first year only in pitavastatin group\textsuperscript{15}). Additionally, as previously mentioned, improved systemic arterial stiffness, assessed by carotid-ankle vascular index (CAVI), due to pitavastatin might result in reduced CV events in the other subgroup analysis of TOHO-LIP\textsuperscript{16}). CAVI essentially reflects the stiffness of the arterial tree from the origin of the aorta to the ankles, and may be a potential therapeutic target for cardiometabolic complications. These findings may indicate that pitavastatin reduced CV events through the amelioration of inflammation and arterial stiffening. So what is the newly supplied pleiotropic effect of pitavastatin in this subgroup analysis? Regarding the mechanism for the superiority of pitavastatin in preventing CV events, we propose the following hypotheses.

First, we propose the pharmacological action of pitavastatin on vascular endothelial function as an explanation for the superiority of this statin. Pitavastatin has been reported to restore impaired endothelial function in \textit{in vivo} and \textit{in vitro} studies, suggesting its pharmacological action related to the reduction of pro-inflammatory response and enhancing nitric oxide production\textsuperscript{9, 36}). Besides, Hitsumoto \textit{et al.}\textsuperscript{ reported the implication of low LPL mass as a marker of coronary vasospasm in early stage atherosclerosis, which is characterized by endothelial dysfunction. Additionally, we previously found the association of CAVI with endothelial function assessed by flow-mediated dilation\textsuperscript{37}), and the fact that appropriate therapeutic approaches in diabetic patients simultaneous improved CAVI and LPL mass\textsuperscript{25, 38}). We therefore speculate that, in TOHO-LIP, pitavastatin-induced improvement of endothelial function was expressed as decreased CAVI and increased LPL mass\textsuperscript{25, 38}). There were few patients with low LPL mass (less than 50 ng/mL), atorvastatin has been reported to increase LPL mass\textsuperscript{40}). There were few patients with low LPL mass in the present study, which may have led to the different result. Furthermore, our previous \textit{in vitro} study revealed that atorvastatin enhanced LPL expression in skeletal muscle, but not in adipose tissue. On the contrary, pitavastatin enhances LPL expression also in adipose tissue, resulting in stronger increase in LPL mass in whole body than atorvastatin\textsuperscript{31, 32}).

Second, elimination of insulin resistance by pitavastatin may exert a direct or indirect anti-arteriosclerotic effect. LPL, which degrades circulating

| Table 4. Association of change in LPL mass during the first year with each endpoint |
| --- |
| **Model 1** |
| **Primary end point** | **Secondary end point** | **3P-MACE** |
| **HR (95% CI)** | **P value** | **HR (95% CI) | **P value** | **HR (95% CI) | **P value** |
| ΔLPL mass (1 ng/mL increase) | 0.960 | 0.0497 | 0.952 | <0.001 | 0.940 | 0.011 |
| ΔLPL mass (1 SD increase) | 0.521 | 0.082 | 0.495 | 0.008 | 0.375 | 0.046 |
| **Model 2** |
| **Primary end point** | **Secondary end point** | **3P-MACE** |
| **HR (95% CI) | **P value** | **HR (95% CI) | **P value** | **HR (95% CI) | **P value** |
| ΔLPL mass (1 ng/mL increase) | 0.961 | 0.100 | 0.951 | 0.003 | 0.929 | 0.013 |
| ΔLPL mass (1 SD increase) | 0.589 | 0.184 | 0.532 | 0.021 | 0.416 | 0.091 |

Cox proportional-hazards analyses.

Model 1: adjusted for gender, diabetes, hypertension and history of ACS and/or coronary revascularization.

Model 2: adjusted for gender, diabetes, hypertension and history of ACS and/or coronary revascularization and pitavastatin administration.

The primary end point, cardiovascular death, sudden death of unknown origin, nonfatal acute myocardial infarction, nonfatal stroke, transient ischemic attack and heart failure requiring hospitalization. Secondary end point, the primary end point plus coronary revascularization. 3P-MACE, nonfatal stroke, nonfatal myocardial infarction and cardiovascular death.

LPL, lipoprotein lipase; HR, hazard ratio; CI, confidence interval; 3P-MACE, 3-point major adverse cardiovascular events; SD, standard deviation.
TG in the bloodstream, is produced mainly in adipocytes and skeletal muscle cells stimulated by insulin, and LPL production is inhibited when insulin function is obstructed\(^1\). Moreover, we have reported the significance of low LPL mass as an indicator of insulin resistance\(^2\)\(^3\)\(^4\). On the other hand, unlike atorvastatin, pitavastatin is speculated to have insulin-sensitizing effect\(^4\), and improved insulin sensitivity is associated with the suppression of systemic oxidative stress independent from glycemic control\(^4\)\(^1\). Accordingly, in the present subgroup study with over 90% of the subjects having diabetes, pitavastatin therapy may have contributed to CV event prevention through improvement of insulin sensitivity as indicated by increased LPL mass. However, we observed no remarkable improvement in severity of diabetes in this study. A large-scale and long-term cohort study is needed to clarify the effect of pitavastatin on diabetes control.

Third, LPL production enhanced by pitavastatin may promote the hydrolysis of circulating atherogenic triglyceride rich lipoproteins (remnant or intermediate lipoproteins)\(^4\). In CHIBA study, pitavastatin but not atorvastatin reduced TG and increased HDL-C in patients with metabolic syndrome\(^1\). It has been reported that pitavastatin stimulated in vitro LPL activity in 3T3-L1 preadipocytes more potently than atorvastatin, which may facilitate the increase in HDL through efficient metabolism of TG-rich lipoproteins\(^3\). Additionally, we previously reported that all of the conventional lipid parameters contributed independently to systemic arterial stiffening in logistic regression models, although TG showed the largest area under the receiver-operating-characteristic curve for predicting high CAVI\(^8\). However, in the TOHO-LIP, there was no difference in TG-lowering effect between pitavastatin and atorvastatin during the 240-week observation period, suggesting that this mechanism of TG-lowering effect potentially resulting from enhanced LPL production may not be greatly involved in CV event prevention by pitavastatin.

It seems strange that the prevalence of diabetes was lower in subjects with secondary end point compared with those without secondary end points (Table 2). This result is difficult to explain because diabetes is generally a contributing factor to cardiovascular events. A plausible explanation is that insulin-resistant diabetics might benefit more from pitavastatin compared with non-diabetics. However, in a Cox model that included diabetes as a confounder, ΔLPL mass was identified as an independent contributor to the cardiovascular event. In addition, in the TOHO-LIP main study\(^3\), the presence or absence of diabetes was not associated with the event-preventing effect of pitavastatin. Further validation is warranted.

There are several limitations in this study. First, the TOHO-LIP main study was conducted as an open-label trial with inherent limitations. However, the independent event committee adjudicated all end point events while blinded to the assigned group. Moreover, to compensate slightly for the open-label trial design, the primary end point did not include coronary revascularization procedures because the decision for coronary revascularization is made by physicians who are aware of the assigned treatment group. Second, unlike the main study, this subgroup analysis was a retrospective, single-center study using the TOHO-LIP database. The sample size was small, which could be a significant obstacle in showing a significant relationship. Third, when this study was designed, the LDL-C target level was set at 100 mg/dL, which is inadequate according to current guideline\(^6\). Fourth, the limitation of this study includes the lack of data on some potential confounders such as proteinuria and smoking status. In addition, CRP, which was mentioned as a supplemental file in the main manuscript, was excluded from the analysis in this study due to the small amount of data (7.6% in all participants). The end point of this study was CV disease, but serum BNP, a marker of heart failure, was not included in the evaluation. Finally, the change in LPL mass for the first year only was analyzed. This short duration was chosen in order to ensure high follow-up rate and include as many subjects as possible for this analysis with a small sample size.

**Conclusions**

Pitavastatin administration reduced CV events more efficaciously than atorvastatin despite similar LDL cholesterol-lowering effect of the two statins. Increased LPL mass during the first year by pitavastatin treatment may be associated with this efficacy.

**Acknowledgement**

The authors wish to thank Fusako Watanabe (Division of Vascular Function, Toho University Sakura Medical Center, Chiba, Japan) and Aki Hagiwara (Medical clerk, Toho University Sakura Medical Center, Chiba, Japan) for collection and assembly of data.
Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure Statement

Dr. Moroi received research grants from Bayer Yakuhin, Ltd., Sanofi KK, MSD KK, Novartis Pharma, Ltd., Teijin Pharma Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., and Nihon Mediphysics, Ltd. All other authors have nothing to disclose.

References

1) Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation, 2004; 110: 1061-1068
2) Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet, 2006; 368: 1155-1163
3) Corsini A, Bellosta S, Baetta R, Fumagalli R, Paolletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 1999; 84: 413-428
4) Sever PS, Dalhoff B, Poulet NR, Wedel H, Beavers G, Caulfield M, Collins R, Kjeldsen SE, Kristensen A, McInnes GT, Mohsen J, Nøien M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet, 2003; 361: 1149-1158
5) Arca M, Gaspardone A. Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs, 2007; 67 Suppl 1: 2942
6) Saito Y. Pitavastatin: an overview. Atheroscler Suppl, 2011; 12: 271-276
7) Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S. A 52-week, randomized, open-label, parallel group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther, 2008; 30: 1089-1101
8) Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, Shinohara H, Tamura Y. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol, 2008; 125: 136-138
9) Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohyama M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N. Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology Investigators. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb, 2008; 15: 345-350
10) Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302
11) Choi JY, Choi CU, Hwang SY, Jeong MH, KAMIR-NIH Investigators. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol, 2018; 122: 922-928
12) Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidemia. Diabetes Obes Metab, 2011; 13: 1047-1055
13) Mita T, Nakayama S, Abe H, Gosho M, Iida H, Hirose T, Kawamori R, Watada H. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig, 2013; 4: 297-303
14) Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, Nishikawa T, Kodama T, Tada N, Saito Y. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis, 2008; 201: 345-352
15) Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, Saito N, Shiba T, Sugimoto H, Fujioka T, Chiba T, Nishizawa K, Usui S, Iwasaki Y, Tatsuno I, Sugi K, Yamashita J, Yamamura S, Shirai K. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol, 2020; 305: 139-146
16) Saiki A, Watanabe Y, Yamaguchi T, Ohiro M, Nagayama D, Saito N, Kanayama M, Takahashi M, Shimizu K, Moroi M, Miyashita Y, Shirai K, Tatsuno I. CAVI-

Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: January 19, 2021   Published online: February 27, 2021
lowering Effect of Pitavastatin may be Involved in Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. J Atheroscler Thromb, 2020; in press. doi: 10.5551/jat.60343
17) Nilsson-Ehle PA, Garfinkel A.S, Schotz M.C. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem, 1991; 49: 667-693
18) Saxena U, Klein M.G, Goldberg I.J. Transport of lipoprotein lipase across endothelial cells. Proc Natl Acad Sci U S A, 1991; 88: 2254-2258
19) Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta, 1993; 216: 113-123
20) Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol, 1995; 15: 1086-1093
21) Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, et al. Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res, 2001; 33: 412-416
22) Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract, 2007; 76: 93-101
23) Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Miyashita Y, Shirai K. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract, 2006; 74: 242-248
24) Ohira M, Miyashita Y, Ebisuno M, Saiki A, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Shirai K. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract, 2007; 78: 34-41
25) Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagumo A, Murano T, Shirai K, Tatsuno I. Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab Syndr Obes, 2014; 7: 313-319
26) Hitsumoto T, Yoshinaga K, Noike H, Kanai M, Shirai K. Clinical significance of preheparin serum lipoprotein lipase mass in coronary vasospasm. Jpn Circ J, 2001; 65: 539-544
27) Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, Shirai K. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis, 2000; 153: 391-396
28) Nagayama D, Endo K, Ohira M, Yamaguchi T, Ban N, Kawana H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shirai K. Effects of body weight reduction on cardio-ankle vascular index (CAVI). Obes Res Clin Pract, 2013; 7: e139-e145
29) Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract, 2002; 56: 181-187
30) Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract, 1999; 46: 35-41
31) Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb, 2005; 12: 163-168
32) Ohira M, Endo K, Saiki A, Miyashita Y, Terai K, Murano T, Watanabe F, Tatsuno I, Shirai K. Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase. Metabolism, 2012; 61: 1452-1460
33) Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scand J Clin Lab Invest, 2014; 74: 285-295
34) Roberts W.C. The Friedewald-Levy-Fredrickson formula for calculating low-density lipoprotein cholesterol, the basis for lipid-lowering therapy. Am. J. Cardiol., 1988; 62: 345-346
35) Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant, 2013; 48: 452-458
36) Katsiki N, Reiner Z, Reiner ET, Al-Rasadi K, Pirro M, Mikhailidis PD, Sahbekar A. Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opin Pharmacother, 2018; 19: 279-286
37) Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int J Clin Pract, 2011; 65: 1200-1201
38) Nagayama D, Ohira M, Saiki A, Shirai K, Tatsuno I. Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients. Int Heart J, 2014; 55: 337-341
39) Kobayashi J, Maruyama T, Masuda M, Shinomiya M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta, 2001; 314: 261-264
40) Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, Otsuka M, Ito Y, Shirai K. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb, 2004; 11: 341-347
41) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Ohira M, Oyama T, Miyashita Y, Shirai K. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract, 2010; 64: 1796-1801
42) Nakagomi A, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, Shimizu W. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. J Atheroscler Thromb, 2015; 22: 1158-1171
43) Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K. Effect of weight loss using formula diet on renal function in obese
patients with diabetic nephropathy. Int J Obes (Lond), 2005; 29: 1115-1120
44) Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, Yamada N. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci, 2002; 71: 2403-2412
45) Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I. Lipid parameters are independently associated with cardio-ankle vascular index (CAVI) in healthy Japanese subjects. J Atheroscler Thromb, 2018; 25: 621-633
46) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S; Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984